1. Home
  2. GRF vs GRML Comparison

GRF vs GRML Comparison

Compare GRF & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Capital Growth Fund Inc.

GRF

Eagle Capital Growth Fund Inc.

N/A

Current Price

$10.09

Market Cap

40.1M

Sector

Finance

ML Signal

N/A

GRML

Greenland Mines Ltd. Common Stock

N/A

Current Price

$0.40

Market Cap

41.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
GRF
GRML
Founded
1989
N/A
Country
United States
United States
Employees
N/A
5
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
40.1M
41.9M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
GRF
GRML
Price
$10.09
$0.40
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.1K
3.0M
Earning Date
01-01-0001
05-13-2026
Dividend Yield
3.70%
N/A
EPS Growth
N/A
N/A
EPS
1.16
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.71
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.47
$0.27
52 Week High
$11.85
$0.45

Technical Indicators

Market Signals
Indicator
GRF
GRML
Relative Strength Index (RSI) 46.43 52.14
Support Level $9.96 $0.31
Resistance Level $10.81 $0.43
Average True Range (ATR) 0.14 0.06
MACD -0.01 0.01
Stochastic Oscillator 46.11 68.53

Price Performance

Historical Comparison
GRF
GRML

About GRF Eagle Capital Growth Fund Inc.

Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.

About GRML Greenland Mines Ltd. Common Stock

Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.

Share on Social Networks: